Key facts
- Link Therapeutics’s last known valuation is $12.7M (Jul 2025).
- It has raised $7.9M; the latest was Early Stage VC ($5.8M) in Jul 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, Kyoto University Innovation Capital, ITOCHU Technology Ventures, Kobe University Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Link Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Link Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Link Therapeutics
Developer of treatment methods designed for targeting antibodies and searching for pathogenic auto-antibodies. The company conducts research and development to elucidate the pathology of diseases caused by auto-antibodies and to create therapeutic methods that target auto-antibodies, enabling doctors to improve the health of patients.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2022
- Employees
- 5
- Website
- link-therapeutics.com/
- Ownership
- Privately Held (backing)
Link Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Link Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Link Therapeutics in its N-PORT filings yet. We sweep new filings monthly.